Fewer, further

AmorChem plans to fund portfolio companies for longer with second fund

AmorChem hopes to garner higher returns with its second early stage life sciences fund by financing fewer projects further into development.

The Montreal VC raised C$44.2 million (US$34.4 million) toward a planned C$50 million (US$38.9 million) fund that will

Read the full 392 word article

User Sign In